The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
The Latest research study released by DBMR “Global Schnitzler Syndrome Disease Treatment Market” with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and ...
Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. The NICE Topic Selection Oversight Panel (TSOP), ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback